AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03206164 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asynchronous, eLearning Intervention
Description: 20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
Study NCT02802046 — intervention group
Intervention type: RADIATION
Intervention: Computed tomographic angiography of coronary artery
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Patients are given, for up to 4 weeks, Oxycodone 5m PRN every four hours (up to 30 tablets)
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Patients are given, for up to 4 weeks, Tramadol 50mg PRN every 6 hours (up to 30 tablets)
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: Tylenol 1000 mg: take as needed every 8 hours
Study NCT04598256 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic procedure
Description: Esophagogastroscopy and colonoscopy
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam
Description: Meloxicam 15 mg as need once per day
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: •Gabapentin 200 mg with morning and evening Tylenol dose
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/ritonavir
Description: Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine/Tenofovir disoproxil fumarate
Description: 200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet taken orally once daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Description: 300-mg tablet taken orally once daily
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaxalone
Description: Metaxalone 800mg TID
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 300-mg tablet taken orally twice daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine
Description: 300-mg tablet taken orally twice daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: 200-mg tablet taken orally once daily
Study NCT00608569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emtricitabine
Description: 200-mg tablet taken orally once daily
Study NCT03829878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP101
Description: Orally administered donor derived full spectrum microbiota
Study NCT03829878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for CP101
Study NCT03190733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
Study NCT03190733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
Study NCT04064008 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Z Revision Femoral Stem
Description: Total Hip Total Hip Arthroscopy
Study NCT01467778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
Study NCT00801814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Second Control
Description: 0g of PGX
Study NCT04003350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20mg
Description: Esomeprazole 20mg daily
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Decreasing dosages from 21 to 7 mg over 12 week period
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine patch
Description: Decreasing dosage from 21 to 7 mg over 12 weeks
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine lozenge
Description: 4 mg nicotine lozenge: dosage according to package directions for 16 weeks
Study NCT01467778 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELAPR
Description: ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
Study NCT01467778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
Study NCT01467778 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ELAPR
Description: Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
Study NCT03448874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seal-G MIST System
Description: Seal-G MIST is an adjunct device that will be applied adjunctively to cover standard closure techniques.
Study NCT00668356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: didanosine
Description: 28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
Study NCT00668356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: didanosine
Description: 28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
Study NCT02178839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β- glucan
Description: 8.5 g/d of Oat Supplement Containing 3g β- glucan
Study NCT02178839 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 8.5 g/d Maltodextrin
Study NCT02487342 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk
Description: small serving (217 mL) of british semi-skimmed milk
Study NCT02487342 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: orange fruit-juice
Description: small serving (217 mL) of orange juice
Study NCT01311635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, current small-particle tablet
Description: 3x100 mg per oral, single dose in fasted state
Study NCT03561402 — intervention group
Intervention type: DRUG
Intervention: Teriflunomide
Description: Each patient will receive 1 tablet (14 mg) on a daily basis.
Study NCT01311635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, new small-particle tablet
Description: 3x100 mg per oral, single dose
Study NCT01311635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981, new large-particle table
Description: 3x100 mg per oral, single dose in fasted state
Study NCT03441672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning of Screening
Description: Interactive technology game providing education about prenatal screening and what the results may mean.
Study NCT00732004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Hydrogel Contact Lenses
Study NCT02835170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous immunoglobulin
Description: Autologous immunoglobulin (total IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
Study NCT00732004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x PMBH preserved MPS
Study NCT00732004 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1x Polyquad/Aldox MPS
Study NCT04011371 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure
Description: Cyanoacrylate glue embolization targeting venous insufficiency
Study NCT00746200 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (electro)acupuncture
Description: Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
Study NCT02835170 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).~(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)
Study NCT03870841 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945
Description: PC945, nebulized
Study NCT05346107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by Nab-paclitaxel (Nab-P) ,continuously combined with dual HER2 blockage
Description: The patients were treated with PldCHP (pegylated liposomal doxorubicin 35mg/m2, cyclophosphamide 600mg/m2, trastuzumab 8 mg/kg loading, then 6 mg/kg, pertuzumab 840 mg loading, then 420 mg, iv, q3w) for 4 cycles followed by Nab-PHP (Nab-Paclitaxel 260mg/m2, trastuzumab 6 mg/kg, pertuzumab 420 mg, iv, q3w) for 4 cycles, with strict monitoring of cardiotoxicity.
Study NCT04801290 — intervention group
Intervention type: PROCEDURE
Intervention: TIPS insertion
Description: Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
Study NCT03967821 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Each patient complete FQoR-15 questionnaire 3 times (before surgery, on Day 1, on Day 2)
Study NCT01790490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.41 mg/kg
Description: 52 minute iv infusion of ketamine 0.41 mg/kg
Study NCT01790490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine 0.71 mg/kg
Description: 52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
Study NCT01790490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg
Description: 52 minute infusion of lorazepam 2 mg. This serves as an active control.
Study NCT00863551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium Chloride
Description: Extended release, 60 mg, oral daily
Study NCT01780792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance Dance Revolution video game play
Description: Individuals play dance dance revolution 3 times a week for 8 weeks
Study NCT00737139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-articular injection of marcaine/epinephrine
Description: 60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
Study NCT00737139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Peri-articular injection of marcaine alone
Description: 60ml of 0.5% Bupivacaine
Study NCT01879410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
Description: The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
Study NCT01879410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
Description: The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
Study NCT00746200 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion
Description: dosage according to prescription directions: 12 weeks
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patch + lozenge
Description: dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
Study NCT01879410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo DISKUS
Description: Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
Study NCT01879410 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo NDPI
Description: Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
Study NCT02774993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Study NCT00296647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupropion + lozenge
Description: dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
Study NCT02774993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00918944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The asthma disease management toolkit available to all practices in the EHR will consist of four elements:~* A data entry tool for capturing asthma control data~* Standardized documentation templates to facilitate severity classification~* Order sets to facilitate ordering controller medications~* An asthma care plan that can be supplied to families
Study NCT00918944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: Three alerts and two reminders will be programmed:~* Alert providers to enter asthma severity classification if none is on file~* Alert providers to prescribe controller medications for persistent asthma if none on file~* Alert providers to complete an asthma care plan if none on file~* Remind providers to review the asthma care plan if it is already on file by providing a link to the form~* Remind providers that educational content is available on-line by providing a web link
Study NCT01860937 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leukapheresis or collection of PBMCs
Study NCT01860937 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide based chemotherapy regimens
Study NCT01860937 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: modified T cells
Study NCT04514263 — intervention group
Intervention type: OTHER
Intervention: OHIP-14 Administration
Description: All patients fulfilled the OHIP-14 questionnaire three times: six hours, seven days and twenty-one days after the biopsy
Study NCT04514263 — intervention group
Intervention type: OTHER
Intervention: VNS Administration
Description: All patients fulfilled the VNS scale three times: six hours, seven days and twenty-one days after the biopsy
Study NCT03965143 — intervention group
Intervention type: DEVICE
Intervention: 3D talar augmentation
Description: Patients with an avascular necrosis of the body if the talar bone will undergo a 3D custom talar augmentation with or without concomitant ankle arthroplasty
Study NCT02098876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Zotarolimus eluting stent
Description: PCI with Resolute stent
Study NCT02098876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience Xpedition everolimus eluting stent
Description: PCI with Xience stent
Study NCT02098876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optical Coherence Tomography (OCT)
Description: Optical coherence tomography (OCT) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. OCT will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area and stent area will be performed for each OCT cross-section from baseline and follow up examinations.
Study NCT02232256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CALPXT96
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
Study NCT02232256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CALPXT96
Description: Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
Study NCT03463772 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard IVF
Description: Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be inseminated using ICSI or conventional IVF according to the seman analysis. All embryos will be cultured to blastocyst stage and be vitrified.
Study NCT03463772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: In vitro maturation
Description: Controlled ovarian stimulation protocol will not performed in this group patients. Transvaginal ultrasound scanning was examined on natural cycle to monitor the follicle size in group B participants. Oocyte retrieval was scheduled once the endometrium had reached at least 6 mm in thickness and there was no follicle larger than 10 mm. After oocyte retrieval, the COCs will be cultured for 28-32h in special IVM media in order to get the matured oocytes. All the metaphase II (MII) oocytes were inseminated by means of intracytoplasmic sperm injection (ICSI). All embryos will be cultured to blastocyst stage and be vitrified.
Study NCT03709992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Chloride
Description: 30 mg of Trospium chloride tablet twice daily
Study NCT03709992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: 0.4 mg of Tamsulosin tablet once daily
Study NCT01592994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RHANI WIves
Description: The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
Study NCT02098876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravascular Ultrasound (IVUS)
Description: Intravascular ultrasound (IVUS) will be performed at baseline to assess plaque burden prior to and after stent deployment as well as to evaluate stent expansion and stent apposition. IVUS will be repeated at one year follow-up to evaluate neo-intimal tissue coverage within the stent and change in plaque area at the stent edges. Offline, manual detection of lumen area, stent area, vessel area (external elastic membrane) and the media-adventitia interface will be performed for each IVUS cross-section from baseline and follow up examinations.